Biogen’s aducanumab was the last great hope for treating Alzheimer’s disease through an approach that the leading lights in the field have believed in for 30 years: siccing a lab-made monoclonal antibody on amyloid plaques in the brain. Now that aducanumab is back from the dead, with the company announcing on Tuesday that additional data overturned its earlier conclusion that the drug had no chance of working, the “amyloid hypothesis” also has a new lease on life — and Biogen (BIIB) has a potentially zillion-dollar moneymaker, should the Food and Drug Administration be persuaded.
Maybe. There are several things to watch for in the weeks and months ahead, and questions that will need to be answered. In no particular order: